Radiomics of Immunotherapeutics Response Evaluation and Prediction

Inclusion Criteria

• •1. Patients with histopathological or cytopathological confirmed solid tumor (including metastatic solid tumor).
• •2. Patients ≥ 18 years of age on the day of baseline CT scan.
• •3. Patients received immune checkpoint inhibitors (ICI) monotherapy or combined with chemotherapy in any line of treatment.
• •4. Patients with at least one measurable target lesion of which minor axis was greater than 15mm and without any local treatment.
• •5. Female with a negative pregnancy test, or male who agree to use barrier methods of contraception through the therapy period.
• •6. Patients with a Eastern Cooperative Oncology Group(ECOG) performance status score of 0 or 1.
• •7. Patients underwent follow-up CT scans with an 6-9-week interval until 365 days after baseline CT scan.
• •8. Patients with baseline and follow-up CT scans which meet the following conditions: a) Spiral computed tomography device of General Electric Healthcare or Siemens with greater than 16 rows of detectors ; b) Peak kilovoltage: 120kV; c) Dose: auto or fixed; d) Slice resolution: not less than 512 pixels multiply 512 pixels; e) Scanning range: from supraclavicular region to 2cm below the costophrenic angle for thorax, and from diaphragm to pubic symphysis for abdomen; f) contrast-enhanced scan utilizing nonionic low- or iso-osmolar contrast agent and including arterial phase, venous phase and delayed phase at least.